Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16763566
Shahbazian D, et al. (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25, 2781-91 16763566
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S422-p - EIF4B (human)
Modsite: RERsRtGsEssQtGt SwissProt Entrez-Gene
Orthologous residues
EIF4B (human): S422‑p, EIF4B (mouse): S422‑p, EIF4B (rat): S422‑p, EIF4B (cow): S422‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p90RSK (human) siRNA inhibition of enzyme, phospho-antibody, transfection of inactive enzyme, transfection of constitutively active enzyme, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE p70S6K (human) genetic knockout/knockin of upstream enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
U0126 serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase
U0126 rapamycin augment treatment-induced decrease
SB203580 serum no effect upon treatment-induced increase
JNK_inhibitor_I serum no effect upon treatment-induced increase JNK inhibitor II
insulin increase
rapamycin insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
serum increase
fluoromethylketone serum inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
eIF3-alpha (human) Induces co-immunoprecipitation

S1147-p - eIF4G (human)
Modsite: VVQRssLsRERGEKA SwissProt Entrez-Gene
Orthologous residues
eIF4G (human): S1147‑p, eIF4G iso3 (human): S1107‑p, eIF4G iso8 (human): S1148‑p, eIF4G (mouse): S1149‑p, eIF4G iso2 (mouse): S1135‑p, eIF4G (rat): S1147‑p, eIF4G (rabbit): S950‑p, eIF4G (cow): S1174‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
fluoromethylketone serum no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
fluoromethylketone serum no effect upon treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
fluoromethylketone serum no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase
insulin increase
U0126 insulin inhibit treatment-induced increase
serum increase
fluoromethylketone serum no effect upon treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
serum increase
fluoromethylketone serum no effect upon treatment-induced increase

S380-p - p90RSK (human)
Modsite: HQLFRGFsFVAtGLM SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): S380‑p, p90RSK iso2 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): , p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
fluoromethylketone serum inhibit treatment-induced increase

S240-p - S6 (human)
Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase

S244-p - S6 (human)
Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase
insulin increase

S422-p - EIF4B (mouse)
Modsite: RERsRtGsEssQtGA SwissProt Entrez-Gene
Orthologous residues
EIF4B (human): S422‑p, EIF4B (mouse): S422‑p, EIF4B (rat): S422‑p, EIF4B (cow): S422‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6K (human) genetic knockout/knockin of upstream enzyme, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE p90RSK (human) siRNA inhibition of enzyme, phospho-antibody, transfection of inactive enzyme, transfection of constitutively active enzyme, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin p70S6K (mouse) increase
rapamycin insulin p70S6K (mouse) inhibit treatment-induced increase
serum increase
rapamycin serum inhibit treatment-induced increase
serum PDK1 (mouse) increase
rapamycin serum PDK1 (mouse) inhibit treatment-induced increase

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
serum PDK1 (mouse) no effect upon treatment-induced increase PDK1 -/-

T412-p - p70S6K (mouse)
Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum PDK1 (mouse) increase
rapamycin serum PDK1 (mouse) inhibit treatment-induced increase

S235-p - S6 (mouse)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin p70S6K (mouse) increase
rapamycin insulin p70S6K (mouse) inhibit treatment-induced increase
serum increase
rapamycin serum inhibit treatment-induced increase

S236-p - S6 (mouse)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin p70S6K (mouse) increase
rapamycin insulin p70S6K (mouse) inhibit treatment-induced increase
serum increase
rapamycin serum inhibit treatment-induced increase

S240-p - S6 (mouse)
Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum PDK1 (mouse) increase
rapamycin serum PDK1 (mouse) inhibit treatment-induced increase

S244-p - S6 (mouse)
Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  ES (stem), hepatocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum PDK1 (mouse) increase
rapamycin serum PDK1 (mouse) inhibit treatment-induced increase